Figure 7 | British Journal of Cancer

Figure 7

From: Inhibition of urokinase plasminogen activator with a novel enzyme inhibitor, wxc-340, ameliorates endotoxin and surgery-accelerated growth of murine metastases

Figure 7

Treatment of animals with WXC-340 abrogated LPS and surgery associated accelerated metastatic tumour growth (*P<0.05). Mice that received WXC-340 before LPS administration and subsequently daily subcutaneous WXC-340 (0.3 mg kg−1) had significantly lower numbers of tumour nodules (A), lung weight (B) and lung-to-body weight ratio (C) than control animals receiving daily PBS (@; P<0.05). Gross specimens (D) and H and E staining (E) demonstrating significantly lower numbers of tumour nodules in the WXC-340-treated mice.

Back to article page